Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 9, 2007, Pages 501-510

  Choi, Min Koo ^a   Jin, Qing Ri ^a   Jin, Hyo Eon ^a   Shim, Chang Koo ^b   Cho, Doo Yeoun ^b   Shin, Jae Gook ^b   Song, Im Sook ^b  

^a Seoul National University   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Affinity; Drug interaction; Metformin; Organic cation transporter (OCT); Tetraalkylammonium (TAA)

Indexed keywords

METFORMIN; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; QUATERNARY AMMONIUM DERIVATIVE; TETRAALKYLAMMONIUM DERIVATIVE; TETRABUTYLAMMONIUM; TETRAHEPTYLAMMONIUM SALT; TETRAHEXYLAMMONIUM BROMIDE; TETRAMETHYLAMMONIUM; TETRAPENTYLAMMONIUM; TETRAPROPYLAMMONIUM; TETRYLAMMONIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL STRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG UPTAKE; GENE OVEREXPRESSION; IC 50; IN VIVO STUDY; MALE; MONOTHERAPY; NONHUMAN; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; CELL LINE; DOGS; DRUG INTERACTIONS; GENE EXPRESSION REGULATION; HUMANS; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; MALE; METFORMIN; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; QUATERNARY AMMONIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38849148341     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.576     Document Type: Article

References (27)

1. Marchetti P, Giannarelli R, di Carlo A, et al. Pharmacokinetics optimization of oral hypoglycemic therapy. Clin Pharmacokinet 1991; 21: 308-317.
2. Klepser TB, Kelly MW. Metformin hydrochloride: an antihyperglycemic agent. Am J Health Syst Pharm 1997; 54: 893-903.
3. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063-2069.
4. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978; 24: 683-693.
5. Tucker GT, Casey C, Phillips PJ, et al. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12: 235-246.
6. Kimura N, Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005; 20: 379-386.
7. Kimura N, Okuda M, Inui KI. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res 2005; 22: 255-259.
8. Urakami Y, Okuda M, Saito H, et al. Hormonal regulation of organic cation transporter OCT2 expression in rat kidney. FEBS Lett 2000; 473: 173-176.
9. Wang DS, Jonker JW, Kato Y, et al. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002; 302: 510-515.
10. Wang DS, Kusuhara H, Kato Y, et al. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol 2003; 63: 844-848.
11. Brown JB, Pedula K, Barzilay J, et al. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 21: 1659-1663.
12. Kwnog SC, Brubacher J. Phenformin and lactic acidosis: a case report and review. J Emerg Med 1998; 16: 881-886.
13. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997; 102: 90-110.
14. Hung DY, Chang P, Cheung K, et al. Cationic drug pharmacokinetics in decreased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharmacol Exp Ther 2002; 301: 1079-1087.
15. Grundemann D, Hahne C, Berkels R, et al. Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J Pharmacol Exp Ther 2003; 304: 810-817.
16. Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23: 545-551.
17. Neef C, Meijer DKF. Structure-pharmacokinetics relationship of quaternary ammonium compounds Correlation of phycochemical and pharmacokinetic parameters. Naunyn Schmiedebergs Arch Pharmacol 1984; 328: 111-118.
18. Zhang L, Gorset W, Dresser MJ, et al. The interaction of n-tetraalkyl ammonium compounds with a human organic cation transporter, OCT1. J Pharmacol Exp Ther 1999; 288: 1192-1198.
19. Dresser MJ, Xiao G, Leabman MK, et al. Interactions of n-tetraalkyl ammonium compounds and biguanides with a human renal organic cation transporter (OCT2). Pharm Res 2002; 19: 1244-1247.
20. Zarghi A, Foroutan SM, Shafaati A, et al. Rapid determination of metformin in human plasma using ion-pair HPLC. J Pharm Biomed Anal 2003; 31: 197-200.
21. Endres CJ, Hsiao P, Chung FS, et al. The role of transporters in drug interations. Eur J Pharm Sci 2006; 27: 501-517.
22. Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117: 1422-1431.
23. Jonker JW, Wagenaar E, Eijl S, et al. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2) in mice abolishes renal secretion of organic cations. Mol Cell Biol 2003; 23: 7902-7908.
24. Zhang L, Schaner ME, Giacomini KM. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther 1998; 286: 354-361.
25. Dresser MJ, Gray AT, Giacomini KM. Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol Exp Ther 2000; 292: 1146-1152.
26. Neef C, Keulemans TPK, Meijer DKF. Hepatic uptake and biliary excretion of organic cations. I. Characterization of three new model compounds. Biochem Pharmacol 1984; 33: 3977-3990.
27. Han YH, Chung SJ, Shim CK. Canalicular membrane transport is primarily responsible for the difference in hepatobiliary excretion of triethylmethylammonium and tributylmethylammonium in rats. Drug Metab Dispos 1999; 27: 872-879.